Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the Hepatorenal Syndrome Market Size from 2025 to 2034?

The market size for hepatorenal syndrome has seen substantial growth in the past few years. Expansion from a base of $1.29 billion in 2024 to a projected $1.37 billion in 2025 is expected, yielding a compound annual growth rate (CAGR) of 6.0%. The significant growth witnessed in the historical period is a result of numerous factors including heightened healthcare spending, an increase in hepatitis infections, enhanced government-led initiatives, an uptick in the occurrences of virus-induced liver diseases, and boosted investment in research and development.

The market size of hepatorenal syndrome is projected to experience substantial growth in the upcoming years, reaching$1.79 billion by 2029 with a compound annual growth rate (CAGR) of 7.0%. This projected growth in the forecast period can be credited to the escalating number of liver diseases, an upsurge in liver transplant programs, growing disease prevalence, an increase in direct kidney injury cases, and a rise in liver disease occurrences. The forecast period is anticipated to witness major trends, including cutting-edge technologies, beneficial government programs, enhanced diagnostic tools, progress in personalized medicine, and developments in nephrology.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22001&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Hepatorenal Syndrome Market?

The hepatorenal syndrome market is anticipated to witness growth due to the increasing incidence of liver diseases. These diseases, which compromise liver function, encompass hepatitis, cirrhosis, fatty liver, liver cancer, genetic disorders, and autoimmune diseases. Liver disease numbers are on the rise due to factors such as obesity, diabetes, alcohol consumption, viral infections, poor nutrition, and exposure to toxins. Conditions such as cirrhosis and acute liver failure, which are a result of growing numbers of liver diseases, increase the likelihood of hepatorenal syndrome (HRS). This is due to severe hemodynamic and kidney dysfunction caused by progressive liver damage. For example, in April 2024, the Office for Health Improvement & Disparities (OHID), an agency of the UK government, stated that UK hospital admissions for liver disease rose to 155.2 per 100,000 patients in 2023, up from 150.6 per 100,000 the previous year. Consequently, the increasing incidence of liver conditions is fueling the expansion of the hepatorenal syndrome market.

Which Key Market Segments Comprise the Hepatorenal Syndrome Market and Drive Its Revenue Growth?

The hepatorenal syndromemarket covered in this report is segmented –

1) By Type: Type 1 Hepatorenal Syndrome; Type 2 Hepatorenal Syndrome; Other Types

2) By Treatment: Liver Transplantation; Terlipressin Infusion; Albumin Infusion; Hemodialysis; Vasoconstrictors; Antibiotic Therapy

3) By Diagnosis: Complete Blood Cell Count; Liver Function Tests; Urinalysis And Urine Electrolytes; Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels

5) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:

1) By Type 1 Hepatorenal Syndrome: Acute Kidney Injury-Associated HRS; Rapidly Progressive Renal Failure

2) By Type 2 Hepatorenal Syndrome: Chronic Kidney Dysfunction-Associated HRS; Slowly Progressive Renal Failure

3) By Other Types: HRS With Cirrhosis; HRS With Acute Liver Failure; HRS With Alcoholic Hepatitis

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22001&type=smp

Which Areas Are Leading Regions in the Hepatorenal Syndrome Market Expansion Across the Globe?

North America was the largest region in the hepatorenal syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatorenal syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theHepatorenal Syndrome Market Over the Coming Years?

Leading firms in the hepatorenal syndrome market are focusing on the advancement of inventive devices like cytopheretic devices. These are aimed at enhancing patient results by controling inflammation, stabalizing kidney functionality and enhancing the effectiveness of Hepatorenal Syndrome (HRS) treatments. The cytopheretic device (Cytosorb) is a unique, externally aided therapy designed to mitigate systemic inflammation and immune reactivity in critically ill patients, including those diagnosed with Hepatorenal Syndrome (HRS). In the recent past, October 2023 to be specific, SeaStar Medical Holding Corporation, an American medical device enterprise, got the FDA’s approval for its Selective Cytopheretic Device (SCD) for the management of hepatorenal syndrome (HRS). This progressive, cell-focused therapy targets excessive inflammation, a major contributor to kidney dysfunction in patients with chronic acute liver failure. Benefitting from immune regulation, the SCD device helps in managing abnormal immune reactions, and this could possibly aid in kidney recovery and enhance patients’ suitability for vital liver transplants. Its efficiency in improving solid organ performance has been evidenced in preclinical and clinical studies across conditions including sepsis, acute kidney injury (AKI), and cardiorenal syndrome.

View the full report here:

https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-global-market-report

How Is the Hepatorenal Syndrome Market Conceptually Defined?

Hepatorenal Syndrome (HRS) is a severe complication of advanced liver disease, characterized by functional kidney failure due to reduced renal blood flow without structural kidney damage. It is caused by splanchnic vasodilation, leading to renal vasoconstriction and decreased glomerular filtration.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22001

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model